Main > > >CARDIOLOGY (CARDIO.). *

---

Absorbable Antibacterial Envelope for Cardiac Implantable Electronic Devices (CIEDs) including Implantable Cardioverter Defibrillators (ICDs) and Pacemakers.
Infection Control.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.08.




Acoustic+Electronic Stethoscope.
USA Clearance Date: 2015. 09.02.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2019. 07.28.




Acute Coronary Syndrome. Treat.:
Eptifibatide Inj. for IV Use. Brand
USA Approval Date: 1998. 05.18.
(*) Company : Merck & Co. Inc.
Patent : Expired
TradeMark: Integrilin
UpDate: 2019. 02.17.




Acute Coronary Syndrome. Treat.:
Ticagrelor Tablets.
Approved in CA; EU; UK & USA.
(*) Company; Patents & TradeMarks Avai-
lable on Request.
UpDate: 2019. 04.15.




Advanced Heart Failure. Treat.: LVAD.
(Left Ventricular Assist Device).
Used for Patients needing Short- or Long-term Mechanical Circulatory Support (e.g., Bridge To Transplant (BTT) or Myocardial Recovery, or Destination Therapy (DT)).
with Magnetic Levitation Technology.
EU Approval Date : 2015. 10.>
>Implanted through Open Heart Surgery
USA Approval Date: 2017. 08.28.>
>Implanted through Open Heart Surgery
USA Approval Date: 2020. 01.07.>
>Implanted through Incision in Chest
Wall
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.08.




Ambulatory ECG Recorder.
EU & USA Approved.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2021. 02.12.




Angina. Chronic. Treat.: Ranolazine ER
Tablets. Brand.
Patent>Expiration: 2019. 05.27.
EU Approval Date : 2008. 04.
USA Approval Sate: 2006. 01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.26.




Angina. Refractory Angina. Treat.: Per-
cutaneous Implant.
EU Approval Date: 2013. 11.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




Angina. Treat.: NitroGlycerin Spray.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.11.




Angina. Treat.: NitroGlycerin SubLingual Powder.
USA Approval Date: 2016. 06.14.
USA Launch Date : 2016. 09.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.18.




Angina. Unstable Angina. Ischemic Complications. Prevention:
Enoxaparin Sodium Injection. BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi-Aventis U.S. LLC.
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Angina. Unstable Angina. Ischemic Complications. Prevention:
Enoxaparin Sodium Injection. GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals.
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Angiography. Syringe with Slip-Ring
Technology. Intended to Inject Contrast
Media or Saline.
EU Approval Date : 2019. 08.14.
USA Approval Date: 2019. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.22.




Aortic Valve Replacement.
EU Approval Date : 2016. 09.29.
USA Approval Date: 2017. 07.05.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 08.31.




Aortic Valved Conduit for Complex Aortic
Valve Surgeries.
Bio-Bentall Procedures>Surgery>Replace-
ment Aortic Valve, Aortic Root &
Ascending Aorta.
Combi.=Bovine Pericardial Tissue+
Gelweave Valsalva Graft
USA Approval Date: 2020. 07.15.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 08.31.




Arrhytmia. 3D Mapping System. Locate the Origin of Arrhythmias. ..
USA Clearance Date: 2017. 02.01.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 02.24.




Arrhytmia. 3D NonInvasive Localization System.
Intended>ACQuisition, Analysis, Display
& storage of cardiac electro-
physiology data and maps for
analysis by a physician.
Intended>Used as Pre-Procedure>Planning
tool for patients with structu-
rally normal hearts undergoing
ablation treatment for idiopa-
thic ventricular arrhythmias.
System Consists of a hand-held 3D came-
ra, & an off-the-shelf laptop
computer with proprietary soft-
ware.
System Uses MRI or CT Scan along with a
standard 12-lead ΕCG to computer-
generate color-coded 3D mapping
images of the heart to indicate
the area of earliest activation.
Using a 3D photograph of the pa-
tient s chest, an MRI or CT
(DICOM image), and a standard 12-
lead ECG, the system generates a
3D rendering of the patient s
heart with superimposed color
coding to indicate the area of
earliest activation.
EU Approval Year : 2017.
USA Approval Date: 2019. 06.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.07.




Arrhytmia. Atrial Fibrillation (AFi).
Diag.: AI (Artificial Intelligence)
Enabled Platform.
USA Launch Date: 2017. 03.16.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2019. 07.04.




Arrhytmia. Atrial Fibrillation (AFi).
Diag.: AI (Artificial Intelligence) (1)
+ECG (Electro Cardio Gram)+Digital
Stethoscope (2)
(1) USA Clearance Date: 2020. 01.28.
(*) Company; Patent (2); & Web-Sites
Acailable on Request.
UpDate: 2020. 02.04.




Arrhytmia. Atrial Fibrillation (AFi).
Diag.: Cloud- & AI (Artificial
Intelligence)-Powered ECG (Electro
Cardio Gram) Analysis.
EU Approval Date : ?
USA Approval Date: 2017. 07.05.
(*) Company; Patent & Product Web-
Site Available on Request.
UpDate: 2019. 02.25.




Arrhytmia. Atrial Fibrillation (AFi).
Diag.: ECG Personal (Mobile) Single
Lead.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Arrhytmia. Atrial Fibrillation (AFi).
Diag.: High Resolution (HR) Imaging &
Non-Contact Mapping System.
Detects & Displays both Standard Volta-
ge-based & HR "Dipole Density (Charge-
Source) Maps". The System uniquely com-
bines "UltraSound (US) Anatomy Construc-
tion" with ability to map the "Electri-
cal-Conduction" of each "HeartBeat" to
Identify Complex Arrhytmias across the
entire "Atrial Chamber". Following each Ablation Treat. the Heart can be "Re-
Mapped" in seconds to continually Visua-
lize any changes from the prior Mapping.
Individualized & Personalized Catheter
Ablation.
IntraCardiac Echocardiography (ICE) &
ElectroAnatomic Mapping Systems.
System ACQuires up to 115,000 Ultra-
Sound (US) Data Points/Minute to rapidly
create an Anatomic Reconstruction of a
chamber of heart & up to 150,000 Biopo-
tential samples/Second to create a 3D
map of cardiac electrical activity of whole chamber in real-time.
System allows ElectroPhysiologists to
tailor TREATs. for each individual pa-
tient & then adapt that TREAT. Iterati-
vely-on the fly-while the patient is
still in ElectroPhysiology (EP) lab.
With System, Physicians can create a
full-chamber, 360-Degree Look at the
Atrium in Real-Time for each individual
patient enabling truly customized TREAT.
for every case using an iterative map,
ablate, re-map, ablate strategy.
EU Approval Date : 2016. 05.04.
USA Approval Date: 2017. 10.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.26.




Arrhytmia. Atrial Fibrillation (AFi).
Mapping. AI-Enabled Electrographic Flow
(Analyze and Visualize the Flow of Action Potentials)
EU Approval Year: 2018.
(*) Company; Patents & Web-Site Avai-
Lable on Request.
UpDate: 2019. 07.04.




Arrhytmia. Atrial Fibrillation (AFi).
Mapping. Cardiac System.
USA Launch Date: 2017. 01.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.




Arrhytmia. Atrial Fibrillation (AFi).
Mapping. HD Grid Catheter SE (Sensor
Enabled).
EU Approval Date : 2017. 12.
USA Approval Date: 2018. 05.03.
(*) Company; Patent: TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.




Arrhytmia. Atrial Fibrillation (AFi). NonValvular AFi (U)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Apixaban Tablets.
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2012. 11.20.
USA Approval Date: 2013. 02.01.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.29.




Arrhytmia. Atrial Fibrillation (AFi). NonValvular AFi (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant
EU Approval Date : ?
USA Approval Date: 2010. 10.19.
Patent No. 01 Expiration Date: 2018. 02.18.
(*) Company; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.30.




Arrhytmia. Atrial Fibrillation (AFi). NonValvular AFi (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant. REVERSAL: IdarucizuMAb
IV Injection 5 g.
USA Approval Date: 2015. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.18.




Arrhytmia. Atrial Fibrillation (AFi).
NonValvular AFi
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Ab.)
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2019. 03.03.




Arrhytmia. Atrial Fibrillation (AFi).
NonValvular AFi
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Bo.)
EU Approval Date : 2009.
EU Approval Date : 2019. 03.13. Next Gen
USA Approval Date: 2015. 03.13.
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2019. 03.14.




Arrhytmia. Atrial Fibrillation (AFi). NonValvular AFi (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2011. 12.19.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 02.04.




Arrhytmia. Atrial Fibrillation (AFi). NonValvular AFi
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Warfarin Sodium Tablets.
(*) Company : Bristol Myers Squibb.
Patent : Expired
TradeMark: Coumadin
Web-Site : www.coumadin.bmscustomerconnect.com
UpDate: 2018. 02.02.




Arrhytmia. Atrial Fibrillation (AFi).
Treat.: Mapping & Ablation System Offe-
ring>
. Single-Shot Pulmonary Vein Isolation
. High Definition Mapping &
. Atrial RadioFrequency Ablation
All in Single Catheter.
EU CE Mark Date: 2020. 06.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.07.




Arrhytmia. Atrial Fibrillation (AFi).
Treat.: Quartz CF (Contact Force) Abla-
tion Catheter SE (Sensor Enabled).
EU Approval Date : 2017. 05.09.
USA Approval Date: 2019. 01.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.28.




Arrhytmia. Atrial Fibrillation (AFi.)
Treat.: RadioFrequency (RF) Ablation.
Bipolar RF Clamps.
Persistent and Long-Standing Persistent
(Non-Paroxysmal) during Open-Heart Concomitant Coronary Artery Bypass Grafting (CABG) &/or Valve Replacement or Repair Procedures.
USA Approval Date: 2011. 12.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.




Arrhytmia. Atrial Fibrillation (AFi).
Treat.: Sotalol IV.>
>1-day Hospital Outpatient Initiation &
faster Dose Escalations for existing
patients
>Reducing Hospital costs and improving
patient satisfaction
>Shortens the Hospital stay from 3 days
to 1 day
USA Approval Date: 2020. 03.10.
(*) Company; Patent & Web-Sites Avai-
lable on Request.
UpDate: 2020. 03.15.




Arrhytmia. Atrial Flutter (AFl). Treat.:
Irrigated Ablation Catheter SE (Sen-
sor Enabled).
USA Approval Date: 2017. 03.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.07.




Arrhytmia. Bradycardia. Diag.: ECG
Personal (Mobile). Single Lead.
USA Approval Date: 2019. 04.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Arrhytmia. Diagnostics. 14 Day Wear
P-Wave Centric ECG Patch Monitor.
CA Approval Date: 2020. 02.
EU CE Mark Date: 2020. 05.26.
USA Clearance Date: 2019. 09.06.
USA Launch Date : 2020. 01.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 05.27.




Arrhytmia. Diagnostics. By Combining:
- Cloud-based Data Analytics
- Machine-Learning capabilities &
- Wearable Biosensing Technology
Company Goal: be the leading provider of first-line Ambulatory Electrocardiogram, or ECG, Monitoring for patients at risk for Arrhythmias.
EU Approval Date : 2014. 12.03.
USA Approval Date: 2012. 02.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.23.




Arrhytmia. Persistent Atrial Fibrilla-
tion (PsAFi). Treat.: CryoAblation
System.
EU CE Mark Date: 2019. 06.01.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 02.02.




Arrhytmia. Remote Diagnostics & Monito- ring System that replicates in-hospital telemetry data, right in the office, by giving physicians 24/7 on-demand access to full disclosure Holter, Event, and MCT (Mobile Cardiac Telemetry) data via a HIPAA-compliant portal APP.
EU Approval Date : 2014. 01.08.
USA Approval Date: 2016. 03.16.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.22.




Arrhytmia. Tachycardia. Diag.: ECG
Personal (Mobile). Single Lead.
USA Approval Date: 2019. 04.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Artificial Intelligence (AI)-Assisted
MRI ACQ. Software.
USA Approval Date: 2019. 10.29.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.30.




Aspirin. MI Prevention? Companion DIAG.:
11-DeHydro Thromboxane B2 ELISA Urine
Test.
USA Approval Date: 2007. 05.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Aspirin+OmeprAzole Delayed Release Ta-
blets.
Indications:
Aspirin Component:
. Reducing the combined risk of death
and nonfatal MI in patients with a
previous MI or unstable angina
pectoris
. Reducing the combined risk of MI and
sudden death in patients with chronic
stable angina pectoris
. Use in patients who have undergone
revascularization procedures (Coronary
Artery Bypass Graft [CABG] or
Percutaneous Transluminal Coronary
Angioplasty [PTCA]) when there is a
pre-existing condition for which
aspirin is already indicated
OmeprAzole Component:
. decreasing the risk of developing
aspirin-associated gastric ulcers in
patients at risk for developing
aspirin-associated gastric ulcers due
to age (≥ 55) or documented history of
gastric ulcers.
USA Approval Date: 2016. 09.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Atrial Arrhytmia. Monitoring & Treat.>
Device by providing a continuous atrial electrogram.
Side Effect of many Cardiac Surgeries.
USA Clearance Date: 2020. 10.06.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 10.07.




Atrial Fibrillation (AFi). AI Mapping
Software.
EU CE Mark Date : ?
USA Approval Date: 2020. 12.09.
(*) Company; Patent; Product Name &
Web-Site Available on Request.
UpDate: 2021. 02.08.




Atrial Fibrillation (AFi). Detection.
Mobile Telemetry Wearable Device.
USA Approval Date: 2019. 04.30.
USA Launch Date: 2021. 01.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.08.




Atrial Fibrillation (AFi). Detection.
Physician Prescribed Wearable Watch-Like
Device.
USA Approval Date: 2020. 10.15.
(*) Companies; TradeMark; USA Patent
APPs. & Web-Site Available on
Request
UpDate: 2021. 02.07.




Atrial Fibrillation (AFi). Detection.
Wearable Watch.
EU CE Mark Date : 2021. 02.10.
IL Approval Date: 2020. 08.06.
(*) Company; Patents & Web-Site Avai-
lable on request
UpDate: 2021. 02.11.




Atrial Fibrillation (AFi). Treat.: En-
doscopic Laser Ablation System.
EU Approval Date : 2019. 03.25.
USA Approval Date: 2020. 05.12.
USA Launch Date: 2020. 06.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 08.27.




Atrial Fibrillation (AFi). Treat.: Tem-
perature Controled Irrigated RadioFre-
quency (RF) Ablation System with Dia-
monds.
EU Approval Date : 2017.
USA Approval Date: 2021. 01.29.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.08.




Atrium Septum Defects (ASD). Treat.:
BioDegradable Septal Occluder (SO)
Metal-Free Framework
EU CE Mark Date: ?
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 08.25.




Atrium Septum Defects (ASD). Treat.:
Septal Occluder (SO).
EU CE Mark Date: 2019. 10.02.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 09.02.




Automated Remote Ischemic Conditioning
Device RIC).
Emergency Medicine.
Indications: - Contrast Induced Acute
Kidney Injury
- Elective Percutaneous
Coronary Intervention
(PCI)
- ST-Elevation Myocardial
Infarction
Intended Use: Patients > 18 Years Under
going:
- CardioThoracic Surgery
- Interventional Cardio
Thoracic Procedures
- Evolving MI
Setting: Ambulance; Hospital.
CA Approval Date: ?
EU Approval Date: 2012. 07.18.
(*) Companies; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 07.14.




Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform.
The proprietary software feature, named "Rotate on Retract" (RoR), is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. It allows the operator to quickly navigate to a targeted lesion by automatically rotating the guidewire upon joystick retraction.
EU Approval Date : 2018. 01.
USA Approval Date: 2018. 03.05.
(*) Company: Corindus Inc. www.corindus.com
UpDate: 2018. 03.06.




BioMarker. Homocysteine. Blood Assay.
CE-Marked & FDA 510(k)-Cleared.
(*) Company; Patents & Web-Site Availa-
ble on Request.
UpDate: 2019. 03.18.




BioTherapeutic Delivery System. Percuta- neous Catheter Delivery System.
Local Delivery of Cell and Gene based Therapies to treat Heart Failure, Myocardial Infarction, Ischemia, and Cardiac Conduction Disorders
EU CE Mark Renewal Date: 2019. 10.08
till 2024. 05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.29.




Cardiac Arrest. Treat.: Cooling. (S)
EU Approval Date: 2008. 01.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.07.




Cardiac Arrest. Treat.: Cooling. (U)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.07.




CardioMyopathy. Treat.: Tafamidis/Tafa- midis Meglumine.
Familial Amyloid CardioMyopathy.
Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM) in Adults
EU Approval Date : 2020. 02.18.
JP Approval Date : 2019. 03.
USA Approval Date: 2019. 05.06.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2020. 02.20.




CardioVascular Disease (CVD). Prognostic
Device.
Availability: AT; CA; CH; DE; IN & UK
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.17.




CardioVascular Implantable Electronic
Device. (CIED). Remote Monitoring Soft-
ware.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.08.




Catheter Ablation Guided by real-time MRI.
Vision-MR Ablation Catheter.
EU CE Mark: 2020. 01.27.
(*) Company: IMRICOR MEDICAL SYSTEMS INC
UpDate: 2020. 02.05.




Cerebral Embolic Protection Device.
Use in Transcatheter Heart Procedures.
- protect the brain during TAVI & TAVR
procedures
- debris such as calcium or tissue can
break loose during the procedure,
travel through the bloodstream towards
the brain and potentially cause
neurological and neurocognitive damage
- protect patients against the risk of
stroke
EU Approval Date: 2020. 03.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.15.




Cerebral Embolic Protection System.
- protect the brain during TAVI & TAVR
procedures
- debris such as calcium or tissue can
break loose during the procedure,
travel through the bloodstream towards
the brain and potentially cause
neurological and neurocognitive damage
- protect patients against the risk of
stroke
EU Approval Year : 2014.
USA Approval Year: 2017.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 08.18.




Chest Pain Triage. Emergency Room (ER).
MagnetoCardioGraphy Platform.
USA FDA 510(k) Clearance: 2019. 03.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.05.




Chronic Heart Failure (CHF). Hospitali-
zation Prognosis Blood ImmunoAssay.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.20.




Chronic Heart Failure (CHF). TREAT.: CCM (Cardiac Contractility Modulation) Therapy
BR Approval Date : 2015. 08.31.
CN Approval Date : 2017. 12.18.
EU Launch Date : ?
RU Approval Date : 2016. 01.26.
USA Approval Date: 2019. 03.21.
USA Approval Date: 2021. 01.20>
>Use of MRI
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 02.07.




Chronic Heart Failure (CHF). TREAT.:
Ivabradine.
INDICATION: Reduce the Risk of Death and
Hospitalization.
With Reduced Ejection Fraction.
CA Approval Date: 2017. 01.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.04.




Chronic Heart Failure (CHF). TREAT.:
Sacubitril/Valsartan Tablets.
Angiotensin Receptor-Neprilysin Inhibi-
tor.
INDICATION: Reduce the Risk of Death and
Hospitalization
With Reduced Ejection Fraction.
EU Approval Date : 2015. 11.29.
USA Approval Date: 2015. 07.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.03.




Chronic Heart Failure (CHF). TREAT.:
Shunt. Left Atrial Pressure (LAP)
Reduction.
EU Approval Date: 2020. 03.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.09.




Chronic Heart Failure (CHF). TREAT.:
TransCatheter Ventricular Enhancement
System.
Less Invasive Procedure.
EU CE Mark Date : 2016. 06.27.
EU CE Mark Extension till: 2024. 05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.02.




Contrast Delivery System.
delivers the power to improve patient safety, minimizing the risk of contrast-induced acute kidney injury (CI-AKI) for coronary catheterizations when compared to manual injection of contrast media.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 01.10.




Cooler Heater Devices.
APP.: CardioPulmonary Surgery.
USA Approval Date: 2020. 02.25.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.01.




Coronary Arteries. Imaging. (C)
Hybrid System with Simultaneous IntraVascular UltraSound (IVUS) and Optical Coherence Tomography (OCT) Capabilities.
Typically used by Interventional Cardiologists to Image Coronary Anatomy during Angioplasty and Stenting Procedures.
CA Approval Date : 2019. 03.16.
USA FDA 510(k) Clearance: 2018. 05.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.21.




Coronary Artery Bypass Grafting (CABG).
Clampless Proximal Anastomosis Device.
EU CE Mark Date : 2021. 01.10.
USA Approval Date: 2021. 03.01.
(*) Company; TradeMark; USA Patent APP.
& Web-Site Available on Request.
UpDate: 2021. 03.02.




Coronary Artery Disease. Calcified Pla-
que. Treat.: Lithotripsy.
Integrates Angioplasty Balloon Catheter
devices with the Calcium-disrupting
power of sonic pressure waves known as
lithotripsy.
EU Approval Date: 2017. 05.15.
EU Launch Date: 2018. 05.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.03.




Coronary Artery Disease. Chronic Total
Occlusion (CTO). ReCanalization. Micro-
Catheter.
USA Approval Date: 2017. 10.26.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.09.




Coronary Artery Disease. DIAG.:
Catheterization. Vascular Closure Sys-
tem.
(*) Company; Patent Assignee; Trade-
Mark & Web-Site Available on Request
UpDate: 2019. 03.14.




Coronary Artery Disease. DIAG.:
Fractional Flow Reserve (FFR). Measure-
ment. Pressure GuideWire.
EU CE Mark Date : ?
USA Approval Date: ?
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2020. 09.14.




Coronary Artery Disease. DIAG.:
Fractional Flow Reseeve (FFR). Measure-
ment: Pressure GuideWire.
USA Approval (3G) Date: 2020. 01.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.10.




Coronary Artery Disease. DIAG.:
Fractional Flow Reserve (FFR)+coronary
Computer Tomography Angiography (cCTA)
Imaging.
CA Approval Date : ?
EU Approval Year : 2011.
JP Approval Date : 2016. 11.17.
USA Approval Date: 2014. 12.01.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2019. 09.23.




Coronary Artery Disease. DIAG.:
Fractional Flow Reserve (FFR)+MicroCa-
theter 2G.
FFR 2G Global Launch : 2017. 10.27.
MicroCa 2G Global Launch: 2020. 07.09.
(*) Company; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2020. 08.25.




Coronary Artery Disease. DIAG.:
GuideWire Fractional Flow Reserve (FFR)
During Percutaneous Coronary Interven-
tion (PCI).
Indications:
to direct a catheter through a blood vessel and to measure blood pressure
in the heart and in the coronary blood vessels.
Patient Outcomes Improvement>
>over Angiography alone.
EU Launch Date: 2016. 05.18.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 03.12.




Coronary Artery Disease. DIAG.: System>
2 Components:
1. a device that records 3D electric
currents via five electrodes attached
to the thorax & collects data from
the resting heart for approximately
four minutes &
2. AI Software APP. that uses multiple
algorithms and machine learning
methods to evaluate the measurements
result, along with a supplementary standard ECG report, are available about one minute later.
No Radiation Exposure
Non-Invasive
Patent>Pending
Study Published in Journal of Electro- cardiology
EU CE Mark: Yes.
(*) Company & Web-Sites Available on
Request.
UpDate: 2020. 01.14.




Coronary Artery Disease. Lipid Core Pla-
que (LCP). Detection & Analysis. Intra-
Vascular UltraSound (IVUS)+Near Infra-
Red Spectroscopy (NIRS). Heart Attack
(Myocardial Infarction. Prognostics.
JP Approval Date : 2017. 08.
JP Launch Date : 2018. 07.31.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.11.




Coronary Artery Disease. Multi Vessel
CAD. NonInvasive Evaluation. Fractional
Flow Reserve (FFR) Device.
3D Reconstruction of Entire Coronary Tree with FFR values along each Vessel.
Delivers Objective FFR Guidance needed
to optimize PCI therapy decisions.
Derived from Routine X-Rays ACQuired during a diagnostic Angiogram procedure.
Performed Intra-Procedurally during Coronary Angiography.
Use during PCI Intervention.
JP Approval Date: 2019. 12.11.
USA Approval Date: 2018. 12.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.12.




Coronary Artery Disease. Prognostics.
Coronary Calcium Algorithm.
USA FDA 510(k) Clearance: 2018. 07.11.
(*) Company : Zebra Medical Vision Ltd.
Web-Site: www.zebra-med.com
UpDate: 2018. 07.12.




Coronary Artery Disease. TREAT.:
BioResorbable Scaffold (“BRS”).
EU Launch Date: 2018. 10.31.
(*) Company; Patent; TradeMarks & Web-
Sites Available on Request.
UpDate: 2019. 03.31.




Coronary Artery Disease. TREAT.: Co-Cr
Stent.>Bifurcation (Site where One Artery Branches from Another).
EU Approval Date : 2011. 05.18.
USA Approval Date: 2017. 03.06.
(*) Companies; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 03.31.




Coronary Artery Disease. TREAT.:
Everolimus-Eluting Coronary Stent System
EU Approval Date : 2017. 10.
JP Approval Date : 2018. 04.
USA Approval Date: 2018. 05.23.
(*) Company : Abbott.
TradeMark: XIENCE Sierra
Web-Site : www.xiencestent.com
UpDate: 2018. 05.24.




Coronary Artery Disease. TREAT.:
Orbital Atherectomy System (OAS). Cla-
ssic Crown+GuideWire.
EU 1st Patient : 2021. 02.08.
EU CE Mark Date : 2021. 01.
JP Approval Date : 2019. 01.02.
USA Approval Date: 2019. 09.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.09.




Coronary Artery Disease. TREAT.:
Planning Software.
USA Clearance Date: 2019. 09.12.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2019. 10.01.




Coronary Artery Disease. TREAT.:
PolyPhosphazene NanoCoated Non-Drug Elu-
ting Co-Cr Stent.
Minimum 1-month (Dual AntiPlatelet Ther- apy (DAPT) Requirement.
EU Approval Year : 2012.
EU Launch Year : 2013.
USA Approval Date: 2017. 03.01.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.15.




Coronary Artery Disease. TREAT.:
Sirolimus Drug Eluting Balloon (DEB)
EU>CE Mark Date: 2020. 05.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.07.




Coronary Artery Disease. TREAT.:
Sirolimus Eluting Stent.
EU Approval Year : 2011.
USA Approval Date: 2019. 02.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.14.




Coronary Balloon.
OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon.
USA 510(k) Clearance: 2018. 03.01.
(*) Company: Cardiovascular Systems Inc. csi360.com
UpDate: 2018. 03.02.




Coronary Heart DIS. (CHD). Prognostics.
Blood Home Test.
Find Your Risk for Heart Attack:
Next G test that assesses your near-term (3-year) risk for a heart attack. It is the first and only clinical test for CHD primary prevention that provides personalized insights based on two types of DNA biomarkers unique to you – genetic and epigenetic.
USA Launch Date: 2021. 01.28.
(*) Companies; TradeMark; USA Patent
APP. & Web-Sites Available on
Request.
UpDate: 2021. 02.04.




Critical Congenital Heart Disease (CCHD). Newborn Screening Application, for the Rad-97™ Pulse CO-Oximeter®.
EU Approval Date: 2018. 02.07.
(*) Company : Masimo. www.masimo.com
TradeMark: Eve
UpDate: 2018. 02.08.




Decreasing Cardiac Performance corresponding to Stage II according to NYHA.: Crataegus Plant Extract.
DE>Approved.
(*) Company : Willmar Schwabe GmbH.
Patent : Expired.
TradeMark: Crataegut
UpDate: 2019. 04.15.




DeFibrillator. Automated External DeFi-
brillator (AED).
Use: Cardio Pulmonary Resuscitation.
USA Approval Date: 2020. 06.02.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.12.




Diabetes Type II. Heart Failure (HF).
Hospitalization Risk Reduction: Dapa-
gliflozin Tablets.
Mechanism: SGLT2 Inhibition.
EU Approval Date : 2019. 08.
USA Approval Date: 2019. 10.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.23.




Diagnostics. ElectroCardioGram (ECG)
Remote Monitoring UnderGarment.
USA Approval Date: 2016. 12.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.31.




Diagnostics. Imaging. UltraSound (US)>>>
>About SubOptimal EchoCardiogram
Up to 20 percent of all resting
echocardiography studies and up to 30
percent of those conducted in critical
care patients can result in suboptimal
echocardiograms.3-6 A suboptimal image
is one in which two or more contiguous
left ventricular segments in any of the
three apical views cannot be
visualized.3,4,7 The use of contrast in
suboptimal echocardiograms may help
with clinical evaluation of the
patient.4,8
>Activation Device>Next G USA Approval
Date: 2020. 08.12.
>Contrast Agent>Perflutren Lipid Micro-
sphere Inj.
>SubOptimal EchoCardiogram
ContraIndication>Shunt>REMOVED
USA>Approval Date: ?
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2020. 09.08.




Diagnostics. Imaging. UltraSound (US).
Software. to empower medical professio- nals without specialized training to perform cardiac ultrasound.
USA Clearance Date: 2020. 02.07.
(*) Company : Caption Health
Company Web-Site: captionhealth.com/
TradeMark : Caption Guidance™
UpDate: 2020. 02.09.




Diagnostics. Troponin. High-Sensitivity Troponin (hsTnI) Assay.
USA FDA 510(k) Clearance: 2018. 06.27.
(*) Company : Beckman Coulter.
Web-Site : www.beckmancoulter.com
UpDate: 2018. 06.28.




Diagnostics. Troponin. Ultra-Sensitive Troponin I Assay (cTnl).
Single Molecule Counting Technology
EU Approval Date: 2017. 06.01.
(*) Company; Patents; & Web-Site Avai-
lable on Request.
UpDate: 2019. 04.01.




DiUretics. Bumetanide Tablets. Generic.
USA Approval Date: 2018. 01.30.
(*) Company: Upsher-Smith Laboratories LLC
UpDate: 2018. 01.31.




DiUretics. SpironoLactone Oral Suspension. 25 mg/5 mL.
Antagonist of Aldosterone.
- Indications:
treatment of NYHA Class III-IV heart
failure and reduced ejection fraction
to increase survival, manage edema,
and to reduce the need for
hospitalization for heart failure; use
as an add-on therapy for the treatment
of hypertension, to lower blood
pressure; the management of edema in
adult cirrhotic patients when edema is
not responsive to fluid and sodium
restrictions.
USA Approval Date: 2017. 08.07.
USA Launch Date : 2017. 10.30.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01




ECG. Connected Device for Universal Use.
Mobile/Portable Hospital grade Digital ECG.
First truly mobile, connected ECG solution that can be applied universally: field screening, point of care, ambulance, Cardiac ICU and at-home monitoring.
The solution comprises of a hospital grade mobile ECG device and mobility software suite of AI assisted solutions for doctors, ambulances and hospitals.
Can be used in both, snapshot short term ECG (30s) and extended observation/monitoring modes in 6 or 12 lead configuration.
Device is being used at a number of leading hospitals in Asia in a variety of use cases. An ECG taken from Device can be analyzed by a live/remote physician and AI engines in seconds. Further, the simple, deskilled use model and ability to record ECGs quickly, has been a major factor in the adoption of this solution for population screening.
Multiple layers of algorithmic and analytics solutions are added to Device to help physicians with actionable insights. This also enables a truly mobile, digital health architecture where third party devices and APPs. can fit in, acting as a base for Software as a Medical Device applications.
EU CE Certified & General Availability EU Launch Date : 2018. 01.04.
USA Approval Date: 2020. 01.10.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.07.




ECG. EchoMD AutoEF Software.
automated clip selection and calculation of left ventricular ejection fraction (EF). EF is the single most widely used metric of cardiac function and used as the basis for many clinical decisions.
USA FDA 510(k) Clearance: 2018. 06.19.
(*) Company : Bay Labs Inc.
Web-Site : baylabs.io
UpDate: 2018. 06.20.




ECG. Electronic Stethoscope. One Device.
(USA>A)
USA Approval Date: 2017. 08.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.29.




ECG. Electronic Stethoscope. One Device.
(USA>E)
USA Clearance Date: 2017. 07.07.
USA Launch Date: 2018. 12.16.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2019. 07.28.




ECG. Electronic Stethoscope. Phonocardio graph. One Device (USA>H)
USA Clearance Date: 2020. 07.14.
(*) Company; Patent; Product Name &
Web-Site Available on Request.
UpDate: 2020. 09.04.




ECG. Personal (Mobile). Six Leads.
USA Clearance Date: 2019. 05.13.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2019. 07.04.




ECG. Wireless Monitor. Multi-Channel Remote ECG Monitor.
USA FDA 510(k) Clearance: 2017. 10.04.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 02.06.




Ejection Fraction (EF) at Point Of Care
(POC) Avaluation.
USA Clearance Date: 2020. 07.23.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 08.25.




ElectroPhysiology Device. Description:
The non-invasive System is a computeri-zed system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardio-graphic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures.
One of the most common reasons for an EP procedure is the diagnosis and treatment of atrial fibrillation. Atrial fibrilla- tion is the most common arrhythmia ..
USA Approval Date: 2018. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 06.04




Guide Extension Catheter.>>
>Creates a Smooth Pathway for balloon
and/or stent delivery by providing
greater flexibility and a smooth
surface. This is important with complex
lesions, calcium, tortuous vessels, and
distal lesions.
>Device Facilitates Delivery of
Interventional Devices in Complex PCI
(percutaneous coronary intervention)
Procedures.
Version 0I EU Launch : 2013. 07.12.
Version 0I USA Launch : 2013. 07.12.
Version II USA Approval: 2017. 03.23.
Version II USA Launch : ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 08.22.




Healthy Individuals. Heart Disease. Ear-
ly Detection.
Correlation between HRV (Heart Rate>
>Variability) & the presence of myocar-
dial ischemia in healthy individuals
without known coronary artery disease
(CAD)
Effortless Stress Test Alternative for>
>early detection of myocardial ischemia
in relatively healthy individuals.
test analyzes 20 minutes of heartrate
data obtained by wearing a standard
heartrate recorder (e.g., Heartrate
strap, smartwatch or bracelet) without
the need for stressful maneuvers or
heart strain making it especially
advantageous for the elderly, impaired,
and weight challenged.
Machine Learning AI Algorithms
EU CE Mark Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.13.




Heart Failure (HF). Early Detection &
Therapeutic Outcome Assessment:
Cardiopulmonary Exercise Testing System
USA Approval Date: 2009. 04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.01.




Heart Failure (HF). Functional Mitral
Regurgitation (FMR). TREAT.: Right
Heart Transcatheter Mitral Valve repair
(TMVr) Device.
Acute Hemodynamic Efficacy.
FMR results from "Dilation of Left>
>Ventricle" (main pumping chamber of the
heart). As left ventricle increases in
size, the mitral valve also expands.
This "dimensional" increase leads to
MR. which reduces amount of blood flow
out of left ventricle. FMR associated
with "reduced functional capacity"
Implantable Device>Proximal Anchor>
>& Distal Anchor. Utilizing proximity of
coronary sinus to mitral annulus
apparatus, , the device is designed to
reduce mitral annulus dilatation upon
deployment, thereby reducing FMR,
Rapidly delivered via the venous
vasculature, ..
Mitral Regurgitation (MR) grades 2+,3+>
>&4+
Non-Surgical Treatment
Percutaneous Mitral Annuloplasty therapy
Reduce Mitral Annulus Dilatation.
AU Approval Date: 2020. 09.02.
EU Approval Date: 2011. 09.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.03.




Heart Failure (HF). Lung Fluid Manage-
ment Device.
USA Launch Date: 2019. 09.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




Heart Failure (HF). reduced Ejection Fraction (rEF). Treat.: Dapagliflozin.
USA Approval Date: 2020. 05.05.
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 08.24.




Heart Failure (HF). Symptomatic. Treat.:
Enalapril Maleate Oral Solution.
USA Approval Date: 2013. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




Heart Failure (HF). Symptomatic. with Reduced Ejection Fraction (HFrEF) After an Acute Myocardial Infarction (AMI).
Survival Improvement: Eplerenone Ta-
blets. Brand.
Mechanism: Aldosterone AntAgonist.
Patent Expiration: 2020.
JP Approval Date : 2007. 07.31.
USA Approval Date: 2002. 09.27.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2019. 03.26.




Heart Failure (HF). Systolic. Reduction
of Signs & Symptoms: Lisinopril Oral
Solution.
USA Approval Date: 2016. 07.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




Heart Failure (HF). Treat.: Cardiac
Resynchronization Therapy (CRT).
Wireless Cardiac Pacing System.
Wireless Endocardial Pacing System.
Wireless Heart Stimulation.
EU Approval Date: 2015. 10.05.
(*) Company; Patents; Technology Trade
Mark & Web-Site Available on Request
UpDate: 2019. 09.01.




Heart Failure (HF). Treat.: Implantable
NeuroModulation Device.
EU Approval Date : 2014. 09.29.
USA Approval Date: 2019. 08.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.06.




Heart Failure (HF). Treat.: Isosorbide
Dinitrate/Hydralazine.HCl.
(in Black Patients)
USA Approval Date: 2005. 06.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.28.




Heart Failure (HF). WireLess Monitor.
USA Approval Date: 2014. 05.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.05.




Heart Failure (HF). With Preserved or
Mid-Range Ejection Fraction (HFpEF or
HFmrEF) (Previously Called Diastolic HF)
Treat.: InterAtrial Shunt Device.
First Transcatheter Device.
EU Approval Date: 2016. 05.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.22.




Heart Function Testing.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.09.




Heart Health for Women>Multi-Lead ECG Heart Health Wearable Bra.
(*) Company; USA Patent APP. & Web-Site
Available on Request.
UpDate: 2019. 09.15.




Heart Transplant.
AU & EU>Approved.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.14.




Heart Transplant. Transport System.
EU Approval Date : 2018. 02.20.
USA Approval Date: 2014. 02.24.
USA Approval Date: 2018. 12.20.>
>Pediatrics Donors.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.16.




HeFH (HEterozygous Familial Hypercholes- terolemia). Treat.: AlirocuMAb Inj.
Heart Attack Risk Reduction in Cardiac
Disease Patients.
Mechanism: PCSK9 Inhibition.
EU Approval Date : 2015. 09.28.
JP Approval Date : ?
USA Approval Date: 2015. 07.24.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




HeFH (HEterozygous Familial Hypercholes-
terolemia). Treat.: Bempedoic Acid Tab.
Adenosine triphosphate-Citrate Lyase
(ACL) Inhibitor. (Non-Statin)
USA Approval Date: 2020. 02.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.29.




HeFH (HEterozygous Familial Hypercholes-
terolemia). Treat.: Bempedoic Acid+Eze-
timibe Tab.
USA Approval Date: 2020. 02.26.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 02.29.




HeFH/HoFH (HEterozygous Familial Hyper-
cholesterolemia/HOmozygous Familial Hy- percholesterolemia). Treat.: EvolocuMAb
Inj.
Heart Attack Risk Reduction in Cardiac
Disease Patients.
Mechanism: PCSK9 Inhibition.
AU Approval Date : ?
CA Approval Date : ?
EU Approval Date : 2018. 05.16.
JP Approval Date : ?
USA Approval Date: 2017. 12.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




High Definition (HD) IntraVascular
UltraSound (IVUS) System>
Global Launch Date: 2015. 09.17.
>MicroCatheter>
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2021. 01.11.




History of MI (Myocardial Infarction).
Reduction of Thrombotic CV Events.
USA Approval Date: 2014. 05.08.
USA Launch Date: 2017. 06.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.17.




HoFH (HOmozygous Familial Hypercholes-
terolemia. Treat.: EvinacuMAb-dgnb.
USA Approval Date: 2021. 02.11.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.12.




HoFH (HOmozygous Familial Hypercholes- terolemia. Treat.: Lomitapide Capsules.
Heart Attack Risk Reduction in Cardiac
Disease Patents.
AT Launch Date: 2015. 04.30.
EU Approval Date: 2013. 07.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.03.




HoFH (HOmozygous Familial Hypercholes- terolemia. Treat.: Lomitapide Capsules.
Heart Attack Risk Reduction in Cardiac
Disease Patents.
CA Approval Date: ?
MX Approval Date: ?
USA Approval Date: 2012. 12.
USA Launch Date: 2014. 02.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.03.




Human iPSC-derived Atrial Cardiomyocytes
for the Discovery and Development of Novel Treatments.
Launch Date: 2018. 07.17.
(*) Company : Axol Bioscience
Web-Site: www.axolbio.com
UpDate: 2018. 08.01.




HyperCholesterolemia. Treat.:
Cholestyramine for Oral Suspension USP.
USA Launch Date: 2018. 06.27.
(*) Company : Ani Pharmaceuticals.
UpDate: 2018. 06.28.




HyperCholesterolemia. Treat.:
Colesevelam.HCI Tablets. Generic.
USA Approval & Launch: 2018. 05.17.
(*) Company : Amneal Pharma.
www.amneal.com
UpDate: 2018. 05.18.




HyperCholesterolemia. Treat.:
FenoFibrate Tablets. Brand.>
>to reduce elevated LDL-C Total-C, TG,
and Apo B, and to increase HDL-C in
adult patients
USA Approval Date: 2007. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01.




HyperCholesterolemia. Treat.: FluvaSta-
tin.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




HyperCholesterolemia. Treat.: Pitava-
Statin Tablets.
USA Approval Date: 2009. 08.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




HyperTension. Medication Adherence. UrinAnalysis.
Launch Date: 2018. 02.01.
(*) Company : Aegis Sciences Corp. www.aegislabs.com.
TradeMark: KardiAssure.
Web-Site : www.aegislabs.com/our-services/kardiassure/
UpDate: 2018. 02.02.




HyperTension. TREAT.: Enalapril Maleate
Oral Solution.
USA Approval Date: 2013. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




HyperTension. TREAT.: Eplerenone Tablets
Brand.
Mechanism: Aldosterone AntAgonist.
Patent Expiration: 2020.
JP Approval Date : 2007. 07.31.
USA Approval Date: 2002. 09.27.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2019. 03.26.




HyperTension. TREAT.: EndoVascular Baroreflex Amplification (EVBA) Procedu-
re Device.
EU Approval Date: 2015. 12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.05.




HyperTension. TREAT.: Implantable Tech-
nology.
EU Approval Date: 2011. 08.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.16.




HyperTension. TREAT.: Lisinopril Oral
Solution.
USA Approval Date: 2016. 07.29.
(*) Company; Patents: TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




HyperTension. TREAT.: Perindopril Erbumine. Generic.
CA Launch Date: 2018. 03.07.
(*) Company: Sandoz Canada.
UpDate: 2018. 03.08.




HyperTension. TREAT.: Perindopril Erbumine/Indapamide.
Generic.
CA Launch Date: 2018. 03.07.
(*) Company: Sandoz Canada.
UpDate: 2018. 03.08.




HyperTension. TREAT.: Sodium Nitroprusside Injection 25mg/mL, 2mL Single Dose Vial. Generic.
Indicated for the Immediate Reduction of Blood Pressure of Adult and Pediatric Patients in Hypertensive Crisis.
USA Approval Date: 2017. 12.19.
(*) Company : Amphastar Pharmaceuticals Inc.
Web-Site: www.amphastar.com
UpDate: 2017. 12.20.




HyperTension. TREAT.: UltraSound (US)
Renal DeNervation System.
EU CE Mark Date: 2012. 02.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.08.




HyperTension. TREAT.: Valsartan Oral Solution.
Angiotensin II Receptor Blocker.
USA Approval Date: 2017. 12.19.
(*) Company : Medicure Inc. www.medicure.com.
TradeMark: Prexxartan.
UpDate: 2017. 12.2




HyperTension+OsteoArthritis. Treat.:
Amlodipine Besylate+Celecoxib Tablets.
USA Approval Date: 2018. 05.31.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 03.15.




HyperTriGlyceridemia. (HTG). Icosapent Ethyl [Ethyl EicosaPentaenoic Acid (E-EPA)]. Indications:
Indication (1): HTG>Treat.>Diet+ Icosa-
pent Ethyl Capsules.
Indication (2): CardioVascular (CV)
Events (in Adult Pa-
tients with HTG & CV
DIS. or Diabetes) RISK
Reduction: Statin+Icosa-
pent Ethyl Capsules.
CV Events:
- Coronary Revascularization.
- Myocardial Infarction (MI)
- Stroke
- Unstable Angina requiring hospitali-
zation.
CA Approval Date (2): 2020. 01.02.
EU Approval Date : 2021. 03.30.
USA Approval Date (1): 2012.
USA Approval Date (2): 2019. 12.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
(*) Patent InValidity?!
UpDate: 2021. 03.31.




HyperTriGlyceridemia. (HTG). Treat.:
Fenofibrate Tablets. Brand.
USA Approval Date: 2007. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01.




HyperTriGlyceridemia. (HTG). TREAT.: Omega-3 Phospholipid.
Status: Phase III.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.31.




Hystology-Validated Image Analysis Soft- ware for evaluating "Atherosclerotic Plaque" Stability from a single Coronary Computed Tomography Angiogram (CTA) enabled by Machine Intelligence.
EU Approval Date : ?
USA Approval Date: 2018. 12.21.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.14.




Implantable Cardiac Monitor (ICM) &
Patient Alerting System for Acute Coro-
nary Syndromes (ACSs.).
Implantation: Like Pacemaker in less
than 1 hour under local
anesthetic.
Indication : Patients have had prior
ACS events including
Myocardial Infarctions
(Heart Attacks) or
unstable Angina and who
remain at high risk for
recurrent ACS events.
EU Approval Date : 2010. 09.21.
SG Successful Implant: 2020. 08.19.
USA Approval Date : 2018. 04.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 08.24.




Integrated Transseptal Puncture & Stee-
rable Sheath System.
EU>CE Mark Commercial Use: 2016. 10.28.
USA>FDA Clearance Date : 2018. 10.11.
USA 1st Clinical Use Date: 2019. 06.12.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 11.04.




Left Atrial Appendage (LAA) Closure De-
vice. (U>At.)
In Arrhytmia>Atrial Fibrillation (AFi.)
Patients.
EU >Approved.
JP >Approved.
USA>Launched.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.




Left Atrial Appendage (LAA) Closure De-
vice. (U>Ab.)
Stroke Risk Reduction in NonValvular
AFi Patients.
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2019. 03.03.




Left Atrial Appendage (LAA) Closure De-
vice. (U>Bo.)
Stroke Risk Reduction in NonValvular
AFi Patients.
EU Approval Date : 2009.
USA Approval Date: 2015. 03.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.04.




Left Ventricular Artificial Intelligence
(AI)-Based UltraSound (US) Imaging Ana-
lysis.
FDA Cleared, CE Marked.
(*) Company; Patent; Product Name &
Web-Site Available on Request.
UpDate: 2019. 08.24.




Left Ventricular DysFunction (ASympto-
matic). TREAT.: Enalapril Maleate Oral
Solution.
USA Approval Date: 2013. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




Magnetic Resonance Imaging (MRI) Analy-
sis. Artificial Intelligence (AI) Assis-
tant.
USA Clearance Date: 2017. 09.01.
(*) Company; Patent & Web-Site Availa-
ble on Request.
UpDate: 2019. 03.31.




Mitral Regurgitation. TREAT.: Semi-Rigid
Annuloplasty Ring.
USA Clearance Date: 2018. 06.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.




Mitral Regurgitation. TREAT.: Supra-
Annular Implant>1st TMVR with Atrial-Only Fixation; leaves the Left Ventricle Geometry Intact and minimizes the risks of LVOT obstruction and damage to the left ventricle.
Status: Investigational device.
UpDate (PRs.): 2019. 09.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 12.14.




Mitral Regurgitation. TREAT.: Trans-
Catheter Mitral Valve Implantation
(TMVI) (Replacement)
EU Approval Date: 2020. 01.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.01.




Mitral Regurgitation. TREAT.: Trans-Catheter Mitral Valve Repair (TMVR)
System
EU Launch Year : 2008.
JP Approval Date : 2017. 11.06.
USA Approval Date: 2018. 07.12.>
>3rd Gen.
USA Approval Date: 2019. 03.14.>
>Secondary Mitral Regurgitation (MR)
USA Launch Date : 2013. 10.25.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 03.15.




Mixed Dyslipidemia & Primary Hyperlipi-demia.
is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients.
HyperCholesterolemia.
HyperTriglyceridemia.
Generic Name: PitavaStatin Tablets.
USA Approval Year: 2017.
USA Launch Date: 2nd Quarter 2018.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




Mobile Cardiac Telemetry (MCT) Device.
Provides real-time monitoring and transmission of your ambulatory patients s ECG information. Together with proprietary software, highly customizable reports, and 24/7 monitoring center, the system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians s existing platforms and workflows
USA 510(K) Clearance Date: 2017. 12.18.
(*) Company : Biotricity.
Web-Site:
www.biotricity.com/bioflux/
UpDate: 2017. 12.19.




Myocardial Infarction. Acute. Infarct
Size Reduction: Impulse Catheter System.
Used during PCI.
Acute MI=anterior STEMI
EU CE Mark Date: 2020. 06.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.08.




Myocardial Infarction. Acute. Left Anterior Descending ST-Segment Elevation
Myocardial Infarction (LAD-STEMI).
Treat.: Super Saturated O2 (SSO2) 2nd
Generation (G) Reduce Heart Muscle Damage Following Angioplasty and Stenting.
EU Approval Date: 2020. 05.04.
USA Approval Date: 2020. 03.30.
(*) Company; Patent & Web-Sites Avai-
lable on Request.
UpDate: 2020. 09.11.




Myocardial Infarction. Acute. ST-Segment Elevation Myocardial Infarction [STEMI].
Prevention. Secondary Prevention:
Fondaparinux Sodium.
Synthetic Heparin.
Xa Inhibitor.
(*) Company : Aspen Holdings.
www.aspenpharma.com
Patent : Expired.
TradeMark: Arixtra.
Web-Site :
www.aspenpharma.com/thrombosis/
UpDate: 2018. 02.04.




Myocardial Infarction. Acute. ST-Segment Elevation Myocardial Infarction [STEMI]. Prevention. Secondary Prevention:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2013. 05.24.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 02.04.




Myocardial Infarction. Acute. ST-Segment Elevation Myocardial Infarction [STEMI]. TREAT.: Enoxaparin Sodium Injection.
BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Myocardial Infarction. Acute. ST-Segment Elevation Myocardial Infarction [STEMI]. TREAT.: Enoxaparin Sodium Injection.
GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Myocardial Infarction. Acute. TREAT.
Reduction of Mortality of Hemodynamica-
lly Stable Patients Within 24 Hours:
Lisinopril Oral Solution.
USA Approval Date: 2016. 07.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.




Myocardial Infarction. Acute. TREAT.
SuperSaturated O2 (SSO2). Infarct Reduc-
tion Size.
Market: Hospital.
USA Approval Date: 2019. 04.04.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.09.




Myocardial Infarction. Cause: Unstable Cardiac Lesion Rupture. DIAG.: Predictive Cardiac Blood Test.
The Test Predicts within 5-Years Time Whether an Individual
will have a Heart Attack ..
Launch Date: 2018. 02.27.
(*) Company : SQI Diagnostics Inc.
sqidiagnostics.com
TradeMarks: PULS.
sqidlite




Myocardial Infarction. DIAG.:
High Sensitivity Troponin I Assay.
AU; CL & EU Launch Date: 2019. 04.16.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2019. 08.25.




Myocardial Infarction. DIAG.:
High Sensitivity Troponin I Test.
EU Approval Date: 2018. 11.29.
(*) Company : Quidel Corp.
TradeMark: TriageTrue
UpDate: 2018. 11.30.




Myocardial Infarction. Non–Q-Wave Myocardial Infarction.
Ischemic Complications Prevention: Enoxaparin Sodium Injection. BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Myocardial Infarction. Non–Q-Wave Myocardial Infarction.
Ischemic Complications Prevention: Enoxaparin Sodium Injection. GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Myocardial Infarction. Prevention. Dia-
betes Type II Patients: Canagliflozin
USA Approval Date: 2018. 10.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.31.




Myocardial Infarction. Prevention. Dia-
betes Type II Patients: Semaglutide.
USA Approval Date: 2020. 01.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.18.




Ostial System Dual-Balloon Angioplasty Catheter.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.31.




Patent Foramen Ovale (PFO) Closure. De-
vice.
Recurrent Ischemic Stroke Risk Reduction
USA Approval Date: 2016. 10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.03.




Patent Foramen Ovale (PFO). Closure.
Septal Occluder (SO).
Indication: Prevent Recurrent Ischemic
Stroke.
USA Approval Date: 2018. 04.03.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 09.02.




Percutaneous Coronary Intervention (PCI). AntiCoagulant.
Bivalirudin. (U>B)
in frozen, premixed, ready-to-use formulation.
in 0.9 percent Sodium Chloride Injection.
USA Approval Date: 2018. 01.22.
(*) Company Available on Request.
UpDate: 2018. 01.23.




Percutaneous Coronary Intervention (PCI). AntiCoagulant. Bivalirudin for Injection.
EU Approval Date : 2004. 09.22.
USA Approval Date: 2000. 12.15.
Patents No. 5 & 6 Expiration Date: 2028. 07.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.23.




Percutaneous Coronary Intervention
(PCI). Robotic Assisted.
Vascular Robotics.
JP Approval Date : 2018. 06.09.
USA Approval Date: 2012. 07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.02.




Percutaneous Coronary Intervention
(PCI). Steerable MicroCatheter.
CN Approval Date : 2020. 02.20.
EU Approval Date : ?
USA Approval Dare: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.23.




Post CABG (Coronary Artery Bypass Graft). Vein Graft Disea-
se. Prevention: External Co/Cr Stent.
EU Approval Date: 2013. 02.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 02.25.




PostSurgery. RBS (Retained Blood Syndro- me). Prevention. Clearance Technology.
CA; EU & USA Approval Date: 2010. 12.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.18.




Pulmonary Arterial Hypertension. Treat.:
Epoprostenol for Inj.
USA Approval Date: 2005. 06.
USA Launch Date : 2010. 04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01.




Pulmonary Arterial Hypertension. Treat.:
Macitentan Tablets.
DE Launch Date : 2014. 01.
JP Launch Date : 2015. 06.
USA Launch Date : 2013. 11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.19.




Pulmonary Arterial Hypertension. Treat.:
Selexipag Tablets.
DE Launch Date : 2016. 06.
USA Launch Date: 2016. 01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.19.




Pulmonary Arterial Hypertension. Treat.:
Tadalafil Tablets USP, 20 mg. Generics.
USA Launch Date: 2018. 08.13.
(*) Company: Mylan NV.
UpDate: 2018. 08.14.




Pulmonary Arterial Hypertension. Treat.:
Tadalafil Tablets USP, 20 mg. Generics.
USA Launch Date: 2019. 02.05.
(*) Company: Teva Pharma.
UpDate: 2019. 02.06.




Pulmonary Arterial Hypertension. Treat.:
Treprostinil. Implant System.
Synthetic Analog of Prostacyclin.
USA Approval Date: 2018. 07.31.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2020. 03.02.




Pulmonary Arterial Hypertension. Treat.:
Treprostinil Inhalation Solution.
Synthetic Analog of Prostacyclin.
USA Approval Date: 2009. 07.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 07.26.




Pulmonary Arterial Hypertension. Treat.:
Treprostinil. Injection. SubCutaneous.
Synthetic Analog of Prostacyclin.
USA Approval (Drug) Date: ?
USA Approval (Pump) Date: 2020. 02.24.>
>PreFillable by Specialty Pharmacies.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2020. 03.02.




Pulmonary Arterial Hypertension. Treat.:
Treprostinil. Oral. ER Tablets.
Synthetic Analog of Prostacyclin.
USA Approval Date: 2013. 12.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.02.




Rapid Deployment Device for Surgical
Aortic Valve Replacement.
EU>CE Mark Date : 2014. 04.04.
USA Approval Date: 2016. 08.15.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 08.31.




Ridaforolimus-Eluting Coronary Stent
System.
About Percutaneous Coronary Intervention (PCI).
PCI is a NonSurgical Procedure that often uses a Catheter to place a Stent to Open Blocked Coronary Arteries caused by "Coronary Artery Disease. (CAD)."
EU Approval Date : 2017. 10.26.
USA Approval Date: 2017. 11.30.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2017. 12.01.




Robotic Assisted Angioplasty.
EU Approval Date: 2019. 02.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator)
Bio Envelope.
Natural ExtraCellular Matrix (ECM) Scaffold
USA Launch Date: 2017. 11.03.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.05.




Self-Expanding Transcatheter Heart Valve. For severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.
EU Approval Date: 2018. 02.15.
(*) Company : Edwards Lifesciences C
PR Web-Site:
www.edwards.com/ns20180215
TradeMark : CENTERA
UpDate: 2018. 02.16.




Stethoscope. Single-Patient.
(*) Company; Patent; Product Name & Web-
Site Available on Request.
UpDate: 2020. 10.09.




Stress Agent. Regadenoson Inj.
Mechanism of Action: A2A Adenosine Re- ceptor Agonist.
EU Approval Date : ?
USA Approval Date: 2008. 04.10.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2019. 02.18.




Surgery. Arterial Cannulae Line.
EU Approval Date: 2018. 02.01.
(*) Company : LivaNova PLC.
www.livanova.com.
TradeMark: PureFlex
UpDate: 2018. 02.02.




Surgery. Cardioplegia. Adenosine+Lido- caine+Mg Sulfate Solution.
Cardioplegia: used to intentionally stop
the heart from beating
during cardiac surgery.
USA Launch Date: 2019. 12.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.12.




Surgery. Sternotomy. Bone Hemostat.
USA Introduction Date: 2019. 02.19.
(*) Company : Terumo Cardiovascular
Systems Corp.
TradeMark: BoneSeal
Web-Site :
www.hemostasisllc.com/boneseal.html
UpDate: 2019. 02.20.




Temporary Pacing Guidewire During Trans-
catheter Aortic Valve Replacement (TAVR)
& Balloon Aortic Valvuloplasty (BAV)
Procedures.
USA Clearance Date: 2020. 01.22.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.06.




Temporary Pacing Leads During Transca- theter Aortic Valve Replacement (TAVR)
Procedures.
EU Approval Date: 2019. 05.08.
USA Approval Date: 2016. 10.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.07.




Thoracic Stent Graft System.
Indications: Descending Thoracic Aorta
(DTA) Lesions>
>Blunt Thoracic Aortic Injuries (BTAIs)
>IntraMural Hematomas (IMHs)
>Penetrating Atherosclerotic Ulcers
(PAUs)
>Thoracic Aortic Aneurysms (TAAs)
>Type B Aortic Dissections (TBADs)
Minimally Invasive Repair.
EU Approval Date : 2018. 11.13.
JP Approval Date : 2019. 10.31.
USA Approval Date: 2018. 10.23.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2019. 11.03.




Transcatheter Aortic Valve Implantation
(TAVI). Aortic Stenosis Treat.
Approved in CN; EU; JP & USA.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 09.01.




Transcatheter Aortic Valve Implantation (TAVI). Pre-Operatively Device Sizing & Positioning Evaluation.
Potential Complications Risk Assessment.
Using Computational Modeling & Simula-
tion Technology.
EU Approval Date: 2019. 04.01.
(*) Company; USA Patent APP. & WIPO No.;
TradeMark & Web-Site Available on
Request.
UpDate: 2019. 07.18.




TransCatheter Mitral Valve Implantation
(TMVI) (Replacement)
EU Approval Date: 2020. 01.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.01.



Transcatheter Mitral Valve Replacement (TMVR). Planning Software.
USA FDA Clearance Date: 2019. 06.13.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2019. 08.07.




Tricuspid Valve Reconstruction System.
Treat.: Tricuspid Regurgitation.
EU CE Mark Date: 2018. 04.30.
(*) Company; Patents; Product Name &
Web-Site Available on Request
UpDate: 2020. 08.30.




Tricuspid Valve Repair System.
Minimally Invasive Non-Surgical Solution
Tricuspid Regurgitation.
EU CE Mark Date: 2020. 04.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.13.




UltraSound. Pocket-Sized Wireless Ultra-
Sound Scanner 2nd Version.
For Sale in EU & USA.
UnVeiling Date: 2021. 03.16.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 03.17.




Valves.>Aortic>Repair>BiCuspid Annulo- plasty Device.
USA Approval Date: 2017. 08.15.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.24.




Valves.>Aortic>Repair>TriCuspid Annulo- plasty Device.
EU Approval Year : 2016.
USA Approval Date: 2017. 03.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.24.




Valves>Aortic>Replacement.
EU Approval Date : 2016. 09.29.
USA Approval Date: 2017. 07.05.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2020. 08.31.



Valves.>Aortic>Replacement>Self-Expan-
ding TransCatheter Valve.
TransCatheter Aortic Valve Replacement (TAVR).
Patients at High Risk for Open Heart Surgery.
Severe Aortic Stenosis Patients.
Sizes: 23mm, 26mm, 29mm and 31mm valves.
EU Approval Year : 2007.
USA Approval Date: 2014. 06.12.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 08.13.




Valves.>Aortic>Replacement>Self-Expan-
ding TransCatheter Valve.
TransCatheter Aortic Valve Replacement (TAVR).
Patients at High Risk for Open Heart Surgery.
Severe Aortic Stenosis Patients.
Size: 34 mm.
EU Approval & Launch Date: 2017. 01.17.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 08.13.




Valves.>Aortic>Replacement>Self-Expan-
ding TransCatheter Valve.
TransCatheter Aortic Valve Replacement (TAVR).
TransCatheter Valve-In-Valve Procedures.
First TAVR Device Indicated for Replacement of Failed Surgical Heart Valves Expands Patient Population That Can Benefit from Minimally Invasive Procedure.
Each year, approximately 200,000 people worldwide receive surgical aortic valves, which typically last 15 years or more. When a surgical valve degenerates over time, patients may require another valve replacement. However, some patients are too sick or frail for a second open-heart surgery, and the transcatheter VIV procedure may now provide them with a new treatment option.
EU Approval Date : 2013. 05.
USA Approval Date: 2015. 03.31.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 08.14.




Valves.>Aortic>Replacement>StentLess Valve.
Stented-Like Implantability.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.21.




Valves.>Aortic>Replacement>SutureLess Valve.
EU Approval Year : 2011.
JP Approval Date : 2018. 06.11.
USA Approval Year: 2016.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.21.




Valves.>Aortic>Replacement>TransCathe-
ter Aortic Valve Replacement (TAVR).
One-Year Results Real World Study Re-
sults>Reduced Severe Aortic Stenosis.
EU Approval Year: 2012.
(*) Company; Patent; Press Release Web-
Site & TradeMark Available on
Request.
UpDate: 2019. 03.11.




Valves.>Aortic>Replacement>Valsalva Conduit.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2019. 02.23.




Valves.>Aortic>Replacement>with Glide
Technology (GT).
EU Approval Date : 2010. 03.03.
EU Launch Date : 2016. 04.07.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 0




Valvular Heart Disease. Diag.: AI (Arti-
ficial Intelligence) (1)+Digital Stethos
cope (2).
(1) USA Approval Date: 2020. 01.28.
(*) Company; Patent (2) & Web-Sites
Available on Request.
UpDate: 2020. 02.04.


>CARDIOLOGY (CARDIO.). *'s products
This section has no products